menu
Investors & Media

Press Releases

Press Releases

Keyword Search

May 06, 2020
Ionis reports first quarter 2020 financial results and recent business achievements
May 01, 2020
Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
Apr 22, 2020
Ionis Pharmaceuticals to hold first quarter 2020 financial results webcast
Apr 20, 2020
Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
Apr 08, 2020
Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs
Apr 07, 2020
Ionis Pharmaceuticals to present at upcoming investor conferences
Feb 27, 2020
Ionis Pharmaceuticals to present at upcoming investor conferences
Feb 26, 2020
Ionis provides fourth quarter and full year 2019 financial results
Feb 19, 2020
Ionis Pharmaceuticals to hold 2019 financial results webcast
Feb 11, 2020
Ionis treatment for Alexander disease granted orphan drug status from EMA
Jan 28, 2020
Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Jan 22, 2020
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
Jan 10, 2020
Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
Jan 09, 2020
Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer
Jan 07, 2020
Ionis' neurological franchise marks year of achievement
Jan 06, 2020
Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare Conference
Jan 02, 2020
New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
Load More »